Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)
Борсодержащие носители на основе аминокислот в борон-нейтронозахватной терапии (БНЗТ)
2023-11-23
SCID: 54.1/hmqv5fz4
Discuss with AI
boron deliveryboron neutron capture therapyboronated amino acidsboronophenylalanine (BPA)large amino acid transporter 1 (LAT1)
Figures from the paper
Abstract (AI)
Interest in the design of boronated amino acids has emerged, partly due to the utilization of boronophenylalanine (BPA), one of the two agents employed in clinical Boron Neutron Capture Therapy (BNCT). The boronated amino acids synthesized thus far for BNCT investigations can be classified into two categories based on the source of boron: boronic acids or carboranes. Amino acid-based boron carriers, employed in the context of BNCT treatment, demonstrate significant potential in the treatment of challenging tumors, such as those located in the brain. This review aims to shed light on the developmental journey and challenges encountered over the years in the field of amino acid-based boron delivery compound development. The primary focus centers on the utilization of the large amino acid transporter 1 (LAT1) as a target for boron carriers in BNCT. The development of efficient carriers remains a critical objective, addressing challenges related to tumor specificity, effective boron delivery, and rapid clearance from normal tissue and blood. LAT1 presents an intriguing and promising target for boron delivery, given its numerous characteristics that make it well suited for drug delivery into tumor tissues, particularly in the case of brain tumors.
Key Findings
1
Amino acid-based boron carriers show substantial potential for treating difficult tumors, including brain tumors.
2
Boronated amino acids for BNCT are broadly classified by boron source as boronic-acid or carborane derivatives.
3
Efficient amino acid-based carriers remain an important unmet objective despite progress since BPA development.
4
Key development challenges include tumor specificity, efficient boron delivery, and rapid clearance from normal tissue and blood.
5
The review identifies LAT1 as a promising target for directing boron carriers into tumor tissue, particularly across brain-tumor barriers.
Research Object
amino acid-based boron carriers for Boron Neutron Capture Therapy (BNCT)
Research Subject
their development and use of large amino acid transporter 1 (LAT1) targeting to achieve tumor-specific boron delivery, effective uptake, and rapid clearance from normal tissues and blood
Publication Details
Publication Date
2023-11-23
Journal
Publisher
ISSN
Cited by
49
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest